FDA Approval
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
PR-M04-21-007Apr 09, 2021
Licensing
ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to Gilead Sciences
ProteoNic
PR-M11-20-004Nov 05, 2020
M&A
Gilead Sciences to Acquire Immunomedics
Gilead Sciences
PR-M09-20-NI-18Sep 15, 2020
COVID-19
Gilead’s Remdesivir Receives FDA Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
Gilead Sciences
PR-M08-20-NI-48Aug 31, 2020
Strategic Partnership
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
Gilead Sciences
PR-M07-20-NI-021Jul 15, 2020
COVID-19 Trial Data
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences
PR-M07-20-NI-015Jul 10, 2020
M&A
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
Gilead Sciences
PR-M06-20-NI-028Jun 23, 2020
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
Gilead Sciences
PR-M05-20-NI-041May 28, 2020
COVID-19 Treatment
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
Mylan
PR-M05-20-NI-018May 14, 2020
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
Gilead Sciences
PR-M04-20-NI-003Apr 02, 2020
M&A
Gilead to Acquire Forty Seven for $4.9 Billion
Gilead Sciences
PR-M03-20-NI-003Mar 02, 2020
Coronavirus
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences
PR-M02-20-NI-037Feb 27, 2020
Coronavirus
Gilead Sciences Begins Trial on Treatment for Coronavirus (2019-nCoV)
Gilead Sciences
PR-M02-20-NI-003Feb 04, 2020
Licensing
Gilead Licenses Antiviral Candidates from Novartis
Nice Insight
PAO-M08-19-NI-019Aug 15, 2019
Collaboration
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration
Gilead Sciences
PR-M07-19-NI-046Jul 18, 2019
Capacity Expansion
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
Gilead Sciences
PR-M07-19-NI-043Jul 17, 2019
Announcement
AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease
AbCellera Biologics Inc.
PR-M06-19-NI-017Jun 14, 2019
Appointment
Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
Gilead Sciences
PR-M05-19-NI-081May 29, 2019
HIV
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
Gilead Sciences
PR-M05-19-NI-038May 14, 2019
Leadership
Changes Coming to Gilead Under New Top Exec
Pharma's Almanac
PAO-M05-19-NI-016May 10, 2019